blood component removal

Summary

Summary: Any procedure in which blood is withdrawn from a donor, a portion is separated and retained and the remainder is returned to the donor.

Top Publications

  1. ncbi Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation
    Selmin Ataergin
    GATA Gulhane Faculty of Medicine, Department of Medical Oncology and Bone Marrow Transplantation Unit, 06018 Etlik, Ankara, Turkey
    Am J Hematol 83:644-8. 2008
  2. ncbi Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia
    Lisa C Hudgins
    The Rogosin Institute, New York, New York, USA
    Am J Cardiol 102:1199-204. 2008
  3. pmc Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease
    Annelie Lindberg
    Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset SE 118 83 Stockholm, Sweden
    BMC Gastroenterol 10:73. 2010
  4. ncbi Hypertriglyceridemic pancreatitis: presentation and management
    Wayne Tsuang
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Am J Gastroenterol 104:984-91. 2009
  5. ncbi Effect of low-density lipoprotein apheresis on circulating endothelial progenitor cells in familial hypercholesterolemia
    Alfonso Ramunni
    Department of Internal and Public Medicine, University of Bari, Italy
    Blood Purif 29:383-9. 2010
  6. ncbi An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment
    Atsushi Sakuraba
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    Am J Gastroenterol 104:2990-5. 2009
  7. pmc Treatment of inflammatory bowel disease: a review of medical therapy
    Patricia L Kozuch
    Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    World J Gastroenterol 14:354-77. 2008
  8. ncbi Fibrinogen/LDL apheresis as successful second-line treatment of sudden hearing loss: a retrospective study on 217 patients
    Franz Heigl
    Hettich and Partner, Medizinisches Versorgungszentrum Kempten Allgäu, Kempten, Germany
    Atheroscler Suppl 10:95-101. 2009
  9. pmc Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA
    Yoko Yokoyama
    Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1 1 Mukogawa, Nishinomiya, 663 8501, Hyogo, Japan
    BMC Gastroenterol 13:27. 2013
  10. ncbi [Fibrinogen/LDL apheresis for treatment of sudden hearing loss: an observational study on 152 patients]
    M Canis
    Klinik und Poliklinik für Hals Nasen Ohren Heilkunde der Ludwig Maximilians Universität, Klinikum Grosshadern, Machioninistrasse 15, 81377, Munchen, Deutschland
    HNO 56:961-6. 2008

Detail Information

Publications235 found, 100 shown here

  1. ncbi Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation
    Selmin Ataergin
    GATA Gulhane Faculty of Medicine, Department of Medical Oncology and Bone Marrow Transplantation Unit, 06018 Etlik, Ankara, Turkey
    Am J Hematol 83:644-8. 2008
    ..Lenograstim 7.5 microg/kg/day is as efficious as filgrastim 10 microg/kg/day for autologous PBSC mobilization and transplantation...
  2. ncbi Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia
    Lisa C Hudgins
    The Rogosin Institute, New York, New York, USA
    Am J Cardiol 102:1199-204. 2008
    ..It effectively lowers LDL cholesterol, but target LDL levels are not achieved, and some patients will show progression of cardiovascular disease...
  3. pmc Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease
    Annelie Lindberg
    Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset SE 118 83 Stockholm, Sweden
    BMC Gastroenterol 10:73. 2010
    ....
  4. ncbi Hypertriglyceridemic pancreatitis: presentation and management
    Wayne Tsuang
    Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
    Am J Gastroenterol 104:984-91. 2009
    ..However, large multicenter studies are needed to optimize future management guidelines for patients with HTGP...
  5. ncbi Effect of low-density lipoprotein apheresis on circulating endothelial progenitor cells in familial hypercholesterolemia
    Alfonso Ramunni
    Department of Internal and Public Medicine, University of Bari, Italy
    Blood Purif 29:383-9. 2010
    ..Since a reduction of these cells has been demonstrated to predict atherosclerosis progression, the aim of this study was to verify whether LA can increase the percentage of EPCs...
  6. ncbi An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment
    Atsushi Sakuraba
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
    Am J Gastroenterol 104:2990-5. 2009
    ..The aim of this study was to assess the clinical efficacy and safety of intensive GMA treatment in patients with active UC...
  7. pmc Treatment of inflammatory bowel disease: a review of medical therapy
    Patricia L Kozuch
    Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, USA
    World J Gastroenterol 14:354-77. 2008
    ..Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC...
  8. ncbi Fibrinogen/LDL apheresis as successful second-line treatment of sudden hearing loss: a retrospective study on 217 patients
    Franz Heigl
    Hettich and Partner, Medizinisches Versorgungszentrum Kempten Allgäu, Kempten, Germany
    Atheroscler Suppl 10:95-101. 2009
    ..Fibrinogen/LDL apheresis improves cochlear blood flow by acutely decreasing plasma cholesterol and fibrinogen...
  9. pmc Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA
    Yoko Yokoyama
    Division of Lower Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1 1 Mukogawa, Nishinomiya, 663 8501, Hyogo, Japan
    BMC Gastroenterol 13:27. 2013
    ..In this study, we looked for predictive factors for clinical response to GMA in patients with UC...
  10. ncbi [Fibrinogen/LDL apheresis for treatment of sudden hearing loss: an observational study on 152 patients]
    M Canis
    Klinik und Poliklinik für Hals Nasen Ohren Heilkunde der Ludwig Maximilians Universität, Klinikum Grosshadern, Machioninistrasse 15, 81377, Munchen, Deutschland
    HNO 56:961-6. 2008
    ..The present study shows that apheresis achieved complete or partial remission in 54% of patients even after unsuccessful treatment with another therapy and the therapeutic window lies by approximately 6 weeks...
  11. ncbi Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study
    Yoshihiro Fukuda
    Department of Gastroenterology, Hyogo College of Medicine, 1 1 Mukogawa, Nishinomiya, 663 8501, Japan
    J Gastroenterol 39:1158-64. 2004
    ..We postulated that patients with CD that is refractory to conventional medications might respond to a reduction of granulocytes and monocytes by adsorptive apheresis...
  12. ncbi Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety, and future perspectives
    T Ruuska
    Department of Paediatrics, Tampere University Hospital, Finland
    Inflamm Bowel Dis 15:1049-54. 2009
    ....
  13. ncbi Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia
    Carsten Otto
    Medical Department 2 Grosshadern, University Hospital of Munich Franz von Prümmer Klinik, Bad Brückenau, Germany
    Artif Organs 27:1116-22. 2003
    ..In conclusion, the new whole-blood LDL apheresis with Liposorber D is a safe, simple, and useful modality to reduce LDL cholesterol and lipoprotein(a) in cardiovascular high-risk patients...
  14. ncbi Coronary plaque regression: role of low density lipoprotein-apheresis
    Philip J Barter
    J Am Coll Cardiol 40:228-30. 2002
  15. ncbi Apheresis registry in France: indications, techniques, and complications. French Registry Study Group
    J M Korach
    Intensive Care Unit, Centre Hospitalier, Chalons en Champagne, France
    Ther Apher 4:207-10. 2000
    ..The French Registry for plasma exchange is the largest data base dealing with therapeutic hemapheresis. The registry set-up through the internet is the first step toward an international data base...
  16. ncbi Improved treatment of sudden hearing loss by specific fibrinogen aphaeresis
    Heidrun Ullrich
    Institute of Transfusion Medicine, University of Hamburg, Hamburg, Germany
    J Clin Apher 19:71-8. 2004
    ..No important side effects were seen. In conclusion, specific fibrinogen adsorption is a promising new treatment modality that should be tested in a prospective, randomized controlled trial in patients with sudden hearing loss...
  17. ncbi Is the efficacy of LDL apheresis in ischemic optic neuropathy linked to a reduction in endothelial activation markers?
    A Ramunni
    Division of Nephrology, Department of Internal and Public Medicine, University of Bari, Bari, Italy
    Blood Purif 24:405-12. 2006
    ..0001). LDLA was effective in reducing the values of all evaluated endothelial activation markers, and this trend was correlated with an improvement in the visual field...
  18. ncbi LDL-apheresis accelerates the recovery of nonarteritic acute anterior ischemic optic neuropathy
    Alfonso Ramunni
    Division of Nephrology, Department of Internal and Public Medicine, Universit of Bari, Piazza Giulio Cesare, 11, 70124 Bari, Italy
    Ther Apher Dial 9:53-8. 2005
    ..This improvement had remained stable after 3 months. Thanks to it's effect of antagonizing hemorheologic disorders of the ocular microcirculation, fibrinogen/LDL-apheresis seems to be an efficacious treatment of NAION...
  19. ncbi LDL apheresis in the treatment of non-arteritic ischaemic optic neuropathy: a 6-month follow-up study
    S Guerriero
    Division of Ophthalmology, Department of Ophthalmology and Otorhinolaryngology, University of Bari, Bari, Italy
    Eye (Lond) 23:1343-4. 2009
    ..Verify the recovery of visual capacity after the administration of a combination of LDL apheresis (LA) and conventional therapy (CT). Design, prospective and interventional case series...
  20. ncbi Acute effect of H.E.L.P. treatment on radical scavenging enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma
    V Schettler
    Georg August University, Gottingen, Germany
    Eur J Clin Invest 30:26-32. 2000
    ..g. by redox sensitive transcription factors activated by extracellular oxidative stress. Therefore, granulocyte FRSE may better reflect acute oxidative stress caused by extracorporeal treatment...
  21. ncbi In vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein-hemoperfusion
    Akira Kobayashi
    Kaneka Corporation, Medical Devices Research Group, Medical Devices Division, Osaka, Japan
    Ther Apher 6:365-71. 2002
    ..In addition, the adsorbent showed mechanical stability and absence of hemolysis. In conclusion, the new adsorbent showed the appropriate characteristics for an LDL adsorbent column for use in whole-blood infusion LDL-hemoperfusion...
  22. ncbi Acute effects of lipid apheresis on human serum lipidome
    Sergey Tselmin
    Department of Internal Medicine III, University Hosptial Carl Gustav Carus at the Technische Universität Dresden, Fetscherstr 74, 01307 Dresden, Germany
    Atheroscler Suppl 10:27-33. 2009
    ..The importance of specific changes in particular lipid species remains to be established...
  23. ncbi Low-density lipoprotein apheresis for the treatment of refractory hyperlipidemia
    A Vella
    Division of Endocrinology, Metabolism, Nutrition and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 76:1039-46. 2001
    ..This review examines the role of LDL apheresis in the management of lipid disorders and the evidence available to support its use in clinical practice...
  24. ncbi Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients
    Maria Juliana Majado
    Servicio de Hematologia, Hospital Virgen de la Arrixaca, Murcia, Spain
    J Clin Apher 24:12-7. 2009
    ..6%) and 6 (15.0%) in groups A and B, respectively (P < 0.01). In conclusion LVA can facilitate autologous transplantation in poor-mobilizer-patients, low PA-CD34 should not be an inflexible exclusion factor...
  25. ncbi Homozygous familial hypercholesterolaemia in identical twins
    J Zschocke
    Department of Paediatrics and Institute of Human Genetics, Ruprecht Karls University, 69120, Heidelberg, Germany
    Lancet 361:1641. 2003
  26. ncbi Contact activation in low-density lipoprotein apheresis systems
    Detlef H Krieter
    Department of Nephrology, University of Wurzburg, Wurzburg, Germany
    Artif Organs 29:47-52. 2005
    ....
  27. ncbi Direct adsorption of low-density lipoprotein by DALI-LDL-apheresis: results of a prospective long-term multicenter follow-up covering 12,291 sessions
    Thomas Bosch
    Nephrology Division, Department I of Internal Medicine, University Hospital Munich Grosshadern, Munich, Germany
    Ther Apher Dial 10:210-8. 2006
    ....
  28. ncbi Pleiotropic effects of LDL apheresis
    Alfonso Ramunni
    Division of Nephrology, Department of Internal and Public Medicine, University of Bari, Bari, Italy
    Atheroscler Suppl 10:53-5. 2009
    ..It is still not clear which of the many proposed actions, or others still to be discovered, is the principal vessel protective mechanism...
  29. ncbi [H.E.L.P. apheresis and oxidative stress]
    E Pulawski
    Herz und Diabeteszentrum NRW, Kardiologische Klinik, GeorgStr 11, 32545 Bad Oeynhausen, Germany
    Z Kardiol 92:III38-41. 2003
    ..In H.E.L.P. apheresis, the antioxidative effects prevail. Oxidation of lipids and severe modification of enzymatic and non-enzymatic antioxidants during extracorporeal circulation do not counterbalance the benefit of LDL reduction...
  30. ncbi Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP
    U Julius
    Institute for Clinical Metabolic Research, University Hospital, Dresden, Germany
    Int J Artif Organs 25:1180-8. 2002
    ..4% versus 6.4%) and total protein (17.9% versus 7.8%) were significantly reduced. Lipidfiltration and HELP both resulted in a reduction of plasma viscosity and hemorheologically relevant plasma proteins, like fibrinogen...
  31. ncbi Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim
    C H Weaver
    CancerConsultants.com Inc, Ketchum, ID, USA
    Bone Marrow Transplant 27:S23-9. 2001
    ..An economic analysis evaluating the cost-effectiveness of these three effective schedules is ongoing at the time of this writing...
  32. ncbi Treatment with HELP-apheresis in patients suffering from sudden sensorineural hearing loss: a prospective, randomized, controlled study
    Giovanni Bianchin
    Otorhinolaryngology Unit, Santa Maria Nuova Hospital, Reggio Emilia, Italy
    Laryngoscope 120:800-7. 2010
    ....
  33. ncbi Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia
    Hiroshi Mabuchi
    Department of Internal Medicine, Division of Cardiovascular Genetics, Graduate School of Medical Science, Kanazawa University, Takahara machi 13 1, Kanazawa 920 8641, Japan
    Transfus Apher Sci 30:233-43. 2004
    ..Mechanisms related these clinical improvement remain unclear, and prospective randomized controlled trials should be performed for the new clinical indications of LDL-apheresis...
  34. ncbi World apheresis registry 2003-2007 data
    B Stegmayr
    Department of Internal Medicine and Transfusion Medicine Blood Center, University Hospital, Umea, Sweden
    Transfus Apher Sci 39:247-54. 2008
    ..Fifteen centers from 7 countries have been actively entering data at the internet site from 2003 until 2007. We report on data from the registry so far...
  35. ncbi Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins--reduction of circulating proinflammatory and procoagulatory markers
    Ying Wang
    Institute of Clinical Chemistry, University Hospital Grosshadern, Marchioninistrasse 15, 81377 Munich, Germany
    Atherosclerosis 175:145-50. 2004
    ....
  36. ncbi Hypertriglyceridemia: apheretic treatment
    G Giannini
    Department of Immunohematology, Immunohematology Services, S Martino University Hospital, Genova Italy
    Int J Artif Organs 28:1018-24. 2005
    ..0% for patients treated by cascade filtration and 63.5% for patients treated by plasmapheresis. The removal rates for triglycerides were low possibly as a consequence of early saturation of the filter...
  37. ncbi WBC-containing allogeneic blood transfusion and mortality: a meta-analysis of randomized controlled trials
    Eleftherios C Vamvakas
    Department of Pathology, New York University School of Medicine, New York, New York, USA
    Transfusion 43:963-73. 2003
    ..A meta-analysis was undertaken to examine whether this finding can be generalized across clinical settings and/or transfused RBC components...
  38. ncbi Apheresis-inducible cytokine pattern change in severe, genetic dyslipidemias
    Claudia Stefanutti
    Extracorporeal Therapeutic Techniques Unit Immunohematology and Transfusion Medicine, Department of Molecular Medicine, University of Rome La Sapienza, Umberto I Hospital, Rome, Italy
    Cytokine 56:835-41. 2011
    ....
  39. ncbi C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis
    P M Moriarty
    Lipid, Atherosclerosis, and Metabolic Clinic, 3901 Rainbow Boulevard, 1336 KU Hospital, Kansas City, KS 66160 7374, USA
    Atherosclerosis 158:495-8. 2001
    ..After 6 months of therapy, pre-treatment hsCRP showed an overall mean level decrease of 49%. Preliminary results indicate that LDL apheresis results in a rapid and long-term decrease of serum hsCRP levels...
  40. ncbi Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial
    M Suckfüll
    Klinikum Grosshadern, 81377, Munchen, Germany
    Lancet 360:1811-7. 2002
    ..We aimed to determine whether acute reduction of plasma fibrinogen and serum LDL is effective for treatment of SSHL of suspected vascular origin...
  41. ncbi Recommendations for the use of LDL apheresis
    G R Thompson
    Imperial College, Hammersmith Hospital, London
    Atherosclerosis 198:247-55. 2008
    ..3) LDL apheresis should also be considered for patients with aggressive progressing coronary disease and Lp(a)>60mg/l whose LDL cholesterol remains >3.2mmol/l despite maximal drug therapy...
  42. ncbi [Myocardial perfusion under H.E.L.P. -apheresis. Objectification by PET]
    K P Mellwig
    Herz und Diabeteszentrum NRW, Kardiologische Klinik, GeorgStr 11, 32545 Bad Oeynhausen, Germany
    Z Kardiol 92:III30-7. 2003
    ..17 mmHg 100 g min/ml, p<0.0001) were achieved. Plasma viscosity decreased only by 7.8%. Within 20 hours after single LDL apheresis a 20% improvement of coronary vasodilation capacity was noninvasively demonstrated and quantified...
  43. ncbi Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis
    Zbigniew M Szczepiorkowski
    Transfusion Medicine Service, Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, NH 03756, USA
    J Clin Apher 22:106-75. 2007
    ..The diseases assigned to category IV are discussed in a separate article in this issue...
  44. ncbi Clinical utility of LDL-apheresis in the treatment of sudden hearing loss: a prospective, randomized study
    M Suckfüll
    Department of Otorhinolarnygology, Head and Neck Surgery, Ludwig Maximilians University Munich, University Hospital Grosshadern, Germany
    Acta Otolaryngol 119:763-6. 1999
    ..Re-establishment of vascular endothelial function and improved blood rheology may be the underlying cause. These results must be confirmed in larger-scale trials...
  45. ncbi Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe
    Gilbert R Thompson
    Imperial College, Hammersmith Hospital, London, UK
    Curr Opin Lipidol 21:492-8. 2010
    ..On the basis of clinical experience, these patients tend to have the most severe forms of familial hypercholesterolaemia or markedly elevated LDL cholesterol (LDL-C) levels but are unable to tolerate statin therapy...
  46. ncbi Improved coronary vasodilatatory capacity by H.E.L.P. apheresis: comparing initial and chronic treatment
    Klaus P Mellwig
    Department of Cardiology, Nuclear Medicine and Molecular Imaging, Heart Center North Rhine Westphalia, Bad Oeynhausen, Germany
    Ther Apher Dial 10:510-7. 2006
    ..E.L.P. treatment has a significant impact on coronary vasodilatatory capacity within 20 h leading to an improved overall cardiac perfusion. Nearly the same effect can be seen in patients after their first H.E.L.P. treatment...
  47. ncbi Lipidfiltration--safe and effective methodology to perform lipid-apheresis
    Reinhard Klingel
    Apheresis Research Institute, Stadtwaldguertel 77, 50935 Cologne, Germany
    Transfus Apher Sci 30:245-54. 2004
    ..The Lipidfiltration system is completed by a specifically designed therapy machine with optimised performance characteristics...
  48. ncbi Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001
    A Krebs
    Division of Nephrology, Medical Faculty, University of Ulm, Germany
    Int J Artif Organs 27:137-48. 2004
    ..To compare long-term efficacy and biocompatibility of the 5 most commonly applied LDL-apheresis techniques using a specifically modified calculation method of the area under the curve (AUC) for laboratory parameters...
  49. ncbi Heparin-induced extracorporeal low-density lipoprotein precipitation
    Klaus Peter Mellwig
    Department of Cardiology, North Rhine Westphalia Heart and Diabetes Center, University Hospital, Ruhr University Bochum, Bad Oeynhausen, Germany
    Ther Apher Dial 7:365-9. 2003
    ..This is supposed to be mainly due to the marked reduction of LDL cholesterol and fibrinogen with consecutive improvement of endothelial dysfunction and rheology...
  50. ncbi Quo vadis haemapheresis. Current developments in haemapheresis
    Helmut Borberg
    German Haemapheresis Centre, Deutsches Haemapherese Zentrum, Maarweg 165, D 50 825 Köln, Germany
    Transfus Apher Sci 34:51-73. 2006
    ....
  51. ncbi From membrane differential filtration to lipidfiltration: technological progress in low-density lipoprotein apheresis
    Reinhard Klingel
    Apheresis Research Institute, Cologne, Germany
    Ther Apher Dial 7:350-8. 2003
    ..The system consists of a novel lipid filter with enhanced sieving characteristics and capacity, and is completed by an enhanced therapy machine with an optimized heating unit...
  52. ncbi A systematic review of LDL apheresis in the treatment of cardiovascular disease
    Jeff Thompsen
    Hartford Hospital, Hartford, CT, USA
    Atherosclerosis 189:31-8. 2006
    ....
  53. ncbi Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation
    Iskra Pusic
    Washington University School of Medicine, Siteman Cancer Center, St Louis, Missouri 63110, USA
    Biol Blood Marrow Transplant 14:1045-56. 2008
    ..Patients who fail initial mobilization are more likely to fail remobilization. These findings suggest that there is a need for more effective first-line mobilization agents...
  54. ncbi The German Lipid Apheresis Registry - remaining to be established
    Volker Schettler
    Centre of Nephrology Göttingen, Gottingen, Germany
    Atheroscler Suppl 10:59-61. 2009
    ..In addition, the working group developed standardized report forms, which could be implemented in a software solution to establish a German Lipid Apheresis Registry...
  55. ncbi Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol
    Ivana N Micallef
    Mayo Clinic, Department of Internal Medicine, Division of Hematology Rochester, Minnesota, USA
    Biol Blood Marrow Transplant 15:1578-86. 2009
    ..There were no drug-related serious AEs. These data support that plerixafor plus G-CSF can safely and effectively remobilize patients with NHL who have failed previous mobilization...
  56. ncbi State of the art of low-density lipoprotein apheresis in the year 2003
    Thomas Bosch
    Nephrology Division, Department I of Internal Medicine, University Hospital Munich Grosshadern, Munich, Germany
    Ther Apher Dial 8:76-9. 2004
    ..Prospective randomized studies showed the beneficial effects of cascade filtration on age-related macular degeneration and of heparin-induced LDL precipitation apheresis on acute inner ear deafness...
  57. ncbi Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis
    Zbigniew M Szczepiorkowski
    Transfusion Medicine Service, Department of Pathology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756, USA
    J Clin Apher 25:83-177. 2010
    ..The article consists of 59 fact sheets devoted to each disease entity currently categorized by the ASFA as category I through III. Category IV indications are also listed...
  58. ncbi Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)
    U Kassner
    Charite Universitatsmedizin Berlin, Germany
    Atheroscler Suppl 10:85-8. 2009
    ..Therefore, we designed a prospective, randomized, controlled trial to prove the hypothesis that lipid apheresis decreases vascular events...
  59. ncbi Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis
    G R Thompson
    Department of Cardiology, Hammersmith Hospital, London
    Lancet 345:811-6. 1995
    ..Decreasing lipoprotein(a) seems to be unnecessary if LDL cholesterol is reduced to 3.4 mmol/L or less...
  60. ncbi International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    S Giralt
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 23:1904-12. 2009
    ..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions...
  61. ncbi Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis
    B R Jaeger
    Institute of Clinical Chemistry, University Hospital Grosshadern, Ludwig Maximilians University Munchen, Munich, Germany
    Ther Apher 5:207-11. 2001
    ..Pilot studies on acute retinal ischemia, critical limb ischemia, and sudden hearing loss confirm this observation...
  62. ncbi Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group
    H Mabuchi
    Second Department of Internal Medicine, Kanazawa University School of Medicine, Japan
    Am J Cardiol 82:1489-95. 1998
    ..0088). It is concluded that LDL-apheresis is effective as treatment of CHD in FH heterozygotes, and may become the therapy of choice in severe types of FH...
  63. ncbi Lipoprotein apheresis
    Gilbert R Thompson
    Metabolic Medicine, Imperial College, Hammersmith Hospital, London, UK
    Curr Opin Lipidol 21:487-91. 2010
    ..Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process...
  64. ncbi Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease
    Motohiro Kamimura
    Center of Blood Purification Therapy, Wakayama Medical University, Wakayama, Japan
    Ther Apher 6:467-70. 2002
    ..The complete occlusion of the anterior tibial artery improved as seen on angiography, and the decubitus in her heel also markedly improved after LDL-A therapy. This report supports the clinical benefit of LDL-A for the treatment of PAD...
  65. ncbi Rheopheresis for idiopathic sudden hearing loss: results from a large prospective, multicenter, randomized, controlled clinical trial
    Ralph Mosges
    Institute of Medical Statistics, Informatics und Epidemiology, University of Cologne, Lindenburger Allee 42, 50931, Cologne, Germany
    Eur Arch Otorhinolaryngol 266:943-53. 2009
    ..Also, this may be a second line treatment option for patients refractory to i.v. corticosteroids or hemodilution...
  66. pmc Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood
    V Muller
    Collegium Budapest, Institute for Advanced Study, 1014 Budapest, Hungary
    J Virol 75:2597-603. 2001
    ..The results suggest that extending current HCV models with an LT compartment is not likely to affect current estimates for kinetic parameters and virus production. Estimates for treatment efficacy might be affected, however...
  67. ncbi Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis
    Hiroyuki Hanai
    Department of Medicine, Hamamatsu University, Hamamatsu, Japan
    Digestion 70:36-44. 2004
    ..Accordingly, our aim was to see if adsorptive granulocyte/monocyte apheresis (GMA) can promote remission and spare steroid in patients with steroid-dependent (SD) UC...
  68. ncbi Dendritic cell culture: a simple closed culture system using ficoll, monocytes, and a table-top centrifuge
    Christina M Celluzzi
    Blood and Cell Therapy Development Department, Jerome H Holland Laboratory for the Biomedical Sciences, American Red Cross, Rockville, MD 20855 2743, USA
    J Hematother Stem Cell Res 12:575-85. 2003
    ..The procedure is relatively fast (effective working time 5-6 h), does not impair monocyte function or induce substantial cell activation, and can be performed economically using equipment found in a typical blood banking environment...
  69. ncbi Comparison of different LDL apheresis methods
    Ulrich Julius
    University Hospital Dresden, Medical Clinic III, Fetscherstr 74, 01307 Dresden, Germany
    Expert Rev Cardiovasc Ther 6:629-39. 2008
    ..The lower target values for LDL cholesterol suggested by international guidelines for high-risk patients will certainly require a more widespread use of LDL apheresis...
  70. ncbi Efficacy criteria and cholesterol targets for LDL apheresis
    Gilbert R Thompson
    Imperial College, Hammersmith Hospital, London W12 0NN, United Kingdom
    Atherosclerosis 208:317-21. 2010
    ..Establishing a uniform approach to data collection would facilitate the setting up of national or multi-national registers and might eventually provide the information needed to formulate evidence-based guidelines for LDL apheresis...
  71. ncbi Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
    Claude Gagne
    CHUL du CHUQ, Ste Foy, Quebec, Canada
    Circulation 105:2469-75. 2002
    ..5% (P=0.0001) versus statin-80. Similar significant reductions in LDL-C concentrations were observed for patients with genotype-confirmed HoFH (n=35). Ezetimibe was safe and well tolerated...
  72. ncbi 26 years of LDL--apheresis: a review of experience
    H Borberg
    German Haemapheresis Centre, Deutsches Hämapherese Zentrum, 50825 KOLN Braunsfeld, Maarweg 165, Germany
    Transfus Apher Sci 41:49-59. 2009
    ..Due to the repetitive cycling and re-use LDL-Apheresis is furthermore not only the most efficient but also the most economic approach to extracorporeal LDL-elimination therapy...
  73. ncbi Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study
    T Wendler
    Department I of Internal Medicine, Nephrology Division, University Hospital, Munich Grosshadern, Munich, Germany
    J Clin Apher 18:157-66. 2003
    ..On average, DALI LDL-apheresis could be performed safely and effectively at high blood flow rates up to at least 120 ml/min in patients with good blood access, which significantly reduced treatment time from 142 to 83 min (-42%)...
  74. ncbi DALI-the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results
    L J Dräger
    University of Applied Sciences, Stralsund, Germany
    Eur J Clin Invest 28:994-1002. 1998
    ..DALI stands for direct adsorption of lipoproteins, which describes the basic principle of operation of this newly developed LDL apheresis procedure...
  75. ncbi Low-density lipoprotein apheresis therapy with a direct hemoperfusion column: a Japanese multicenter clinical trial
    Hiromi Tasaki
    Second Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan
    Ther Apher Dial 10:32-41. 2006
    ..We conclude that the new type of LDL adsorption column, one that deals with whole blood, is a promising apheresis therapy for FH patients in view of its efficacy, reduced time for treatment, and safety...
  76. ncbi [Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)]
    D Horstkotte
    Herz und Diabeteszentrum NRW Kardiologische Klinik, GeorgStr 11, 32545, Bas Oeynhausen, Germany
    Z Kardiol 92:III1-5. 2003
    ..This is likely to result from a considerable reduction of LDL cholesterol and fibrinogen with a consecutive improvement of both endothelial function and rheology...
  77. ncbi Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma
    Anna Maria Barbui
    Divisione di Ematologia, Radioterapia and Centro Trasfusionale, Ospedali Riuniti, Bergamo, Italy
    Br J Haematol 116:202-10. 2002
    ..This suggests that autologous transplantation using efficiently purged PBSCs can be performed safely, but confirms the need for innovative protocols for MRD eradication in vivo...
  78. ncbi The effect of low-density lipoprotein apheresis on ocular microcirculation in patients with hypercholesterolaemia: a pilot study
    Naim Terai
    Department of Ophthalmology, Carl Gustav Carus University Hospital, Fetscherstr 74, 01307 Dresden, Germany
    Br J Ophthalmol 95:401-4. 2011
    ..To investigate the effect of low-density lipoprotein (LDL) apheresis on ocular microcirculation in patients with hypercholesterolaemia...
  79. ncbi Influence of single low-density lipoprotein apheresis on the adhesion molecules soluble vascular cellular adhesion molecule-1, soluble intercellular adhesion molecule-1, and P-selectin
    Ewa Pulawski
    Department of Cardiology, Heart Center North Rhine Westphalia, Ruhr University of Bochum, Bad Oeynhausen, Germany
    Ther Apher 6:229-33. 2002
    ..In addition to lipid reduction, single HELP apheresis significantly lowers plasma concentrations of sVCAM-1, sICAM-1, and P-selectin...
  80. ncbi Clinical effectiveness of selective granulocyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis
    Brigitte Habermalz
    Institute for Research in Operative Medicine, University of Witten Herdecke gGmbH, Ostmerheimer Str 200, 51109 Cologne, Germany
    Dig Dis Sci 55:1421-8. 2010
    ..19; CI 0.11-0.34). Homogeneous evidence from seven RCTs shows that GMA apheresis induces a clinical remission in a higher proportion of UC patients as compared to conventional medical therapy...
  81. ncbi Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses
    P M Moriarty
    Lipid, Atherosclerosis, and Metabolic Clinic, University of Kansas Medical Center, 1336 KU Hospital, 3901 Rainbow Boulevard, Kansas City, KS 66160 7374, USA
    Curr Atheroscler Rep 3:156-62. 2001
    ..We also discuss the potential advantages of lipid apheresis for the treatment of patient populations other than those characterized by severe hypercholesterolemia and premature coronary heart disease...
  82. ncbi Management strategies for poor peripheral blood stem cell mobilization
    Rainer Moog
    Institute for Transfusion Medicine, University Hospital Essen, Hufelandstrasse 55, Germany
    Transfus Apher Sci 38:229-36. 2008
    ..Processing of more blood in LVL is achieved by an increase of the blood flow rate and an altered anticoagulation regimen with the occurrence of more citrate reactions...
  83. ncbi Effectiveness of long-term heparin-induced extracorporeal LDL precipitation (HELP) in improving coronary calcifications
    A Ramunni
    Division of Nephrology, Department of Internal and Public Medicine, University of Bari, Bari, Italy
    Int J Artif Organs 26:252-5. 2003
    ....
  84. ncbi Comparison of different low density lipoprotein apheresis machines on brain natriuretic Peptide levels in patients with familial hypercholesterolemia
    Patrick Moriarty
    Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, USA
    Ther Apher Dial 14:74-8. 2010
    ..The increased reduction of BNP by HELP may result from its superior acute alterations of rheological markers...
  85. ncbi Fibrinogen apheresis in the treatment of peripheral arterial disease
    A Ramunni
    Division of Nephrology, Department of Internal and Public Medicine, University of Bari, Bari, Italy
    Blood Purif 25:404-10. 2007
    ..Fibrinogen is mainly responsible for determining the viscosity of whole blood. In peripheral arterial disease (PAD) the fibrinogen concentration seems to affect the microcirculation flow...
  86. ncbi Therapeutic effects of LDL apheresis in the prevention of atherosclerosis
    K Kajinami
    Second Department of Internal Medicine, School of Medicine, Kanazawa University, Japan
    Curr Opin Lipidol 10:401-6. 1999
    ..Since the mechanisms of clinical improvement caused by LDL apheresis extend beyond simple and drastic reduction of LDL cholesterol, further investigation based on recent vascular biological evidence is needed...
  87. ncbi Immunologic changes after transfusion of autologous or allogeneic buffy coat-poor versus white cell-reduced blood to patients undergoing arthroplasty. I. Proliferative T-cell responses and the balance of helper and suppressor T cells
    P Innerhofer
    Department of Anesthesia and Intensive Care, Computer Center, University of Innsbruck, Austria
    Transfusion 39:1089-96. 1999
    ..This study investigated this topic in otherwise healthy patients receiving buffy coat-depleted or WBC-filtered RBCs and undergoing standardized perioperative management...
  88. ncbi Prestorage WBC filtration of RBC units with soft-shell filters: filtration performance and impact on RBCs during storage for 42 days
    Michael Müller-Steinhardt
    Institute of Immunology and Transfusion Medicine, University of Lübeck School of Medicine, Lubeck, Germany
    Transfusion 42:153-8. 2002
    ..Centrifugation of blood containers with newly developed soft-shell WBC filters is more convenient, and so of great interest...
  89. ncbi Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis
    Francois Lefrere
    Département de Biothérapie, Service d Hématologie Adultes, and Laboratoire d Hématologie, Hopital Necker, 75743 Paris Cedex 15, France
    Transfusion 47:1851-7. 2007
    ..This prospective study has evaluated the potential of such method to predict the PBPC mobilization...
  90. ncbi Estimation of haemopoietic progenitor cells in peripheral blood by the Advia 120 and BD vantage flow cytometer: a direct comparison for the prediction of adequate collections
    H M Greenfield
    Department of Haematology, Christie Hospital, Manchester, UK
    Clin Lab Haematol 27:287-91. 2005
    ..13) or LUC count (r = 0.12, P = 0.23). Our results indicate that the LUC population in peripheral blood has no relevance to the subsequent CD34 content of the apheresis product and CD34 cell enumeration by flow cytometry is advocated...
  91. ncbi [Collection of peripheral blood stem cells from ABO incompatible allogeneic donors by using blood cell separator]
    Shu Xuan Ma
    Department of Blood Transfusion, General Hospital of PLA, Beijing 100853, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 13:496-9. 2005
    ..1), with the modified separation factors, and the collected PBSC component can be safely infused into the ABO incompatible recipients without removal of erythrocytes or plasma...
  92. ncbi The effect of peptide stimulation on haematopoietic stem cell mobilisation including engraftment characteristics and a note on donor side effects
    Gameda Barendse
    Department of Haematology and Bone Marrow Transplant Unit incorporating the Searll Laboratory for Research in Cellular and Molecular Biology, Constantiaberg Medi Clinic, Burnham Road, Plumstead 7800, Cape Town, South Africa
    Transfus Apher Sci 32:105-16. 2005
    ....
  93. ncbi Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma
    S Fruehauf
    Department of Tumor Diagnostics and Therapy, Paracelsus Hospital, Osnabrueck, Germany
    Bone Marrow Transplant 39:743-50. 2007
    ..The results of this study thus provide further support for the clinical utility of pegfilgrastim for the mobilization of PBSC following chemotherapy in cancer patients scheduled for transplantation...
  94. ncbi Mobilization and harvesting of peripheral blood stem cells
    Rainer Moog
    Institute for Transfusion Medicine, University Clinics Essen, Germany
    Curr Stem Cell Res Ther 1:189-201. 2006
    ..Muscle and bone pain are frequent adverse events in allogeneic stem cell mobilization but are usually tolerated under the use of analgesics. Spleen enlargement followed by rupture is a serious complication in allogeneic donors...
  95. ncbi Platelet storage lesion: an update on the impact of various leukoreduction processes on the biological response modifiers
    Jerard Seghatchian
    Blood Component Technology and Thrombosis Haemostasis Consultancy, 50 Primrose Hill Road, London NW3 3AA, UK
    Transfus Apher Sci 34:125-30. 2006
    ....
  96. ncbi How free of residual cells and cell antigens is human blood plasma? A comparison of different production methods of human blood plasma and the risk of the products for patients
    Karin Wurm
    Department of Anesthesiology and Intensive Care, Friedrich Schiller University, Jena, Germany
    Transfus Apher Sci 38:149-57. 2008
    ..No remaining antigenic fragments were detected when an additional plasma filter was used...
  97. ncbi Overnight storage of autologous stem cell apheresis products before cryopreservation does not adversely impact early or long-term engraftment following transplantation
    M D Parkins
    Department of Medicine, University of Calgary and Tom Baker Cancer Centre, Calgary, Alberta, Canada
    Bone Marrow Transplant 38:609-14. 2006
    ....
  98. ncbi Markers of platelet activation and apoptosis in platelet concentrates collected by apheresis
    Renata Procházková
    Department of Transfusion Medicine, District Hospital Liberec, Czech Republic
    Transfus Apher Sci 37:115-23. 2007
    ..A product with well-preserved haemostatic function of platelets is the ultimate goal of platelet concentrate production. However, platelet activation and apoptosis are induced by both collection and storage of platelet concentrates...
  99. ncbi Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients
    Saad Akhtar
    Section of Medical Oncology, King Faisal Cancer Center, King Faisal Specialist Hospital and Research Center, P O Box 3354, MBC No 64, Riyadh 11211, Kingdom of Saudi Arabia
    Leuk Lymphoma 49:769-78. 2008
    ..001) and no prior radiation therapy (p = 0.051) had better CD34+ cells collection. Higher first harvest CD34+ cells collection also resulted in early neutrophil (p < or = 0.001) and platelet (p = 0.004) engraftment...
  100. ncbi Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products
    Melinda K Gordon
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 49:531-7. 2008
    ..No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample...
  101. ncbi No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF
    Yair Gazitt
    University of Texas Health Science Center, San Antonio, 78284, USA
    Stem Cells Dev 15:269-77. 2006
    ..02). These results support the hypothesis that higher levels of DCs in the graft might be associated with prolonged survival of autotransplanted NHL patients. Further similar studies are merited in a larger population of NHL patients...

Research Grants35

  1. EVOLUTION OF B PRECURSOR LEUKEMIA IN THE EU-RET MOUSE
    Stephan Grupp; Fiscal Year: 2003
    ..He will immunoprecipitate Rfp-Ret from the pro B cell populations of fetal and healthy adult E(-ret mice as well as from leukemias and compare the levels of tyrosine phophorylation of Rfp-Ret and Rfp-Ret-bound proteins. ..
  2. VIRUS PHOTOINACTIVATION--DIMETHYLMETHYLENE BLUE IN RBC
    Stephen Wagner; Fiscal Year: 2004
    ..abstract_text> ..
  3. POST TRANSPLANT T CELL RECONSTITUTION IN NEUROBLASTOMA
    Stephan Grupp; Fiscal Year: 2005
    ..abstract_text> ..
  4. USE OF mTOR INHIBITORS IN B CELL LEUKEMIA
    Stephan Grupp; Fiscal Year: 2009
    ..These studies will immediately translate to the designs of follow-up studies of these agents. ..
  5. Symposium on Emerging Cardiac Cellular Therapies
    Edward Snyder; Fiscal Year: 2005
    ..abstract_text> ..
  6. Nonmyeloablative Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
    Richard Nash; Fiscal Year: 2006
    ..The unique observations in this study regarding responses and recovery of organs after inducing a sustained remission of SSc will serve to focus and direct other non-transplant research activities. [unreadable] [unreadable] [unreadable]..
  7. RESTENOSIS AND ENDOTHELIAL PROLIFERATION
    Douglas Losordo; Fiscal Year: 2007
    ..Together these studies will result in a better understanding of the mechanisms, which govern EC recovery at sites of balloon injury and may lead to novel therapeutic strategies targeting endothelial recovery. [unreadable] [unreadable]..
  8. Monoclonal Antibody Therapy for Follicular Lymphoma
    Jonathan Friedberg; Fiscal Year: 2007
    ..abstract_text> ..
  9. MethLock vs. heparin as dialysis catheter lock
    Stephen Ash; Fiscal Year: 2008
    ..In Phase II we will implement the protocol in a number of dialysis centers and complete the study as originally proposed or as modified after Phase I. ..
  10. Protection from GVHD with Gene-Modified Donor T Cells
    Richard Nash; Fiscal Year: 2008
    ....
  11. Progenitor Cells in Vascular Biology
    Douglas Losordo; Fiscal Year: 2008
    ..The ultimate goal of these studies is to identify future clinical strategies for tissue repair. ..
  12. Mechanistic study of CHD risk in subjects with high HDLC
    Marina Cuchel; Fiscal Year: 2008
    ....
  13. MPT INHIBITOR IND 50,820 IN FAMILIAL HYPERCHOLESTEROLEM*
    Marina Cuchel; Fiscal Year: 2009
    ..This study would serve as basis for approval of BMS-201038 for hoFH. ..
  14. Phase 3 stem cell transplant for light chain amyloidosis
    Morie A Gertz; Fiscal Year: 2011
    ..In addition, the analysis of clonal precursor B cells in the periphery and kinetics of amyloid formation of the monoclonal light chain will allow us to define and determine the mechanisms of disease progression and response to therapy. ..
  15. ESTROGEN, ANGIOGENESIS AND ENDOTHELIAL PROGENITOR CELLS
    Douglas Losordo; Fiscal Year: 2004
    ..abstract_text> ..
  16. Pheresis Treatment of Bioterrorism-Induced Sepsis
    Stephen Ash; Fiscal Year: 2005
    ..The safety systems of the existing PF system will be modified to meet the needs of the stand-alone system. Finally, an animal model of sepsis will be used to check efficacy and safety of the entire system. ..
  17. OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMA
    Ajay Gopal; Fiscal Year: 2005
    ..We anticipate that these interventions will ultimately enhance the prognosis for patients with relapsed lymphoma by increasing the response and survival rates, while simultaneously minimizing toxicities. ..
  18. Conference-Safeguarding Adult/Pediatric Stem Cell Donors
    Edward Snyder; Fiscal Year: 2004
    ..This Symposium would address the need for such Standards and stimulate the process. AIM 3 will be to publish a summary of the Symposium in a nationally recognized Journal. ..
  19. RESEARCH TRAINING IN TRANSFUSION MEDICINE
    Jeffrey McCullough; Fiscal Year: 2003
    ..abstract_text> ..
  20. Prognostic Modeling of High-Risk Primary Breast Cancer
    Yago Nieto; Fiscal Year: 2003
    ..abstract_text> ..
  21. Proapoptotic Therapy for B-cell Non Hodgkin's Lymphoma
    Ajay Gopal; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  22. Risk of Blood Borne Transmission of CJD
    Shimian Zou; Fiscal Year: 2008
    ..Publishanddisseminateresultsof thestudy. ..
  23. ENGRAFTING SENSITIZED HOSTS WITH NONABLATIVE REGIMENS
    Richard Nash; Fiscal Year: 2002
    ..By lessening the morbidity and mortality associated with conventional conditioning, these studies could significantly change the management of selected inherited red blood cell diseases. ..
  24. Cardiac MDCT for Early Triage of Patients with ACS
    Udo Hoffmann; Fiscal Year: 2008
    ..abstract_text> ..
  25. NOVEL APPROACHES TO IMPROVE AND EXTEND PLATELET STORAGE
    Sherrill Slichter; Fiscal Year: 2001
    ....
  26. Lung Transplantation and Immune Tolerance in Young Recipients
    Richard Nash; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  27. Acquisition of FACSVantage SE Flow Cytometer
    Yair Gazitt; Fiscal Year: 2004
    ..The new equipment will also widen the user's base, save sort time, reduce costs for users and will render sorting affordable to new users, especially in cases where low frequency (<1%) cell populations are sorted. ..
  28. Role of Progenitor Cells in Cardiovascular Medicine
    Douglas W Losordo; Fiscal Year: 2010
    ..Accordingly, in this proposal we will employ a series of in vivo and in vitro model systems to define the role of EPCs in recovery from myocardial ischemia with a goal of developing future therapeutic strategies exploiting these cells. ..
  29. INCREASE/gp120 IMMUNOGENICITY/LINKED ALPHA-GAL EPITOPES
    Uri Galili; Fiscal Year: 2005
    ..We will then also collaborate with a group studying immune responses in monkeys to determine the efficacy of this vaccine in a primate model. ..
  30. Xenograft-like rejection of tumors in a-gal glycolipids
    URI GALILI GALILI; Fiscal Year: 2010
    ..We will study this treatment in a unique mouse model that simulates the pertinent human immunological parameters. Success in the studies in the mouse model will enable us to apply this treatment to cancer patients. ..
  31. CARDINAL BERNARDIN CANCER CENTER, LOYOLA UNIVERSITY
    Patrick Stiff; Fiscal Year: 2002
    ..At the completion of this grant, the Cardinal Bernardin Cancer Center plans to be positioned to successfully apply for a P-30 Cancer Center Support Grant. ..
  32. PREVENTING ANTI-GAL PRODUCTION AGAINST XENOGRAFTS
    Uri Galili; Fiscal Year: 2003
    ..Success in these studies will help in planning effective treatments for preventing anti-Gal response in primate xenografts recipients. | ..
  33. Experimental Uveal Melanoma and Ocular Immune Privilege
    KYLE MCKENNA; Fiscal Year: 2007
    ..abstract_text> ..
  34. Facilitating Cells for Fetal Hematopoietic Transplant
    Laurence Shields; Fiscal Year: 2005
    ..Future directions will be towards the use of this model to explore the role and function of developmentally regulated adhesion molecules and their receptors as they relate to fetal hematopoietic transplantation. ..